SEC Form 4 · accession 0001144204-17-006945
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick O Cope
Officer — SVP & Chief Scientific Officer
Period of report
Feb 6, 2017
Accepted (ET)
Feb 9, 2017 · 11:41 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| NAVB Common Stock, $.001 par valueF1 | Feb 6, 2017 | A | 88,378 | $0.52 | A | 180,593 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Granted in lieu of cash bonus under 2015 and 2016 bonus plans.